With more than 1200 patent families with claims including CRISPR, do you actually know whether you are infringing on third-party rights when using this technology?
Four industry experts provide meaningful insights and feedback in this webinar on the following topics:
Use of CRISPR for model generation (Amélie Rezza, genOway)
Overview of CRISPR patent landscape (Mathieu Fontaine, Questel)
Coverage of specific Merck CRISPR-enabling process (Ajay Rastogi, Merck)
Freedom to use CRISPR/Cas9-based tools (Sandrine Carteau, genOway)
Watch our video :